Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

Regeneron (REGN) announced an expansion of its manufacturing capacity through a new agreement with Fujifilm Diosynth Biotechnologies to manufacture and supply bulk drug product of Regeneron’s ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

FujiFilm Diosynth plans to produce Regeneron's biologic medicines over 10 years in its Holly Springs facility, which is ...

Industrial Operations and Product Supply at Regeneron. “We take our role seriously, and our decision to work with Fujifilm reflects our belief that they will meet our high standards and grow ...

and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products ...

Under the terms of the deal, Tokyo-based Fujifilm Diosynth's facility in Holly Springs, North Carolina will manufacture and supply drug products for Regeneron's biologic medicines for a span of 10 ...